Centerview Partners
Michael Reisman is an experienced investment banking professional currently serving as an Investment Banking Principal at Centerview Partners since May 2019, specializing in healthcare M&A and strategic advisory. Notable transactions include the $900 million sale of Bolt Medical to Boston Scientific, the $1.4 billion sale of Aliada Therapeutics to AbbVie, and the $4.9 billion sale of Eidos Therapeutics to BridgeBio. Prior to Centerview Partners, Michael gained experience at Lazard as an Investment Banking Analyst focusing on healthcare and completed a summer analyst position at J.P. Morgan with a focus on technology. Michael holds a Bachelor of Arts in Economics from the University of Chicago, graduating in 2018.
This person is not in the org chart
This person is not in any teams
This person is not in any offices